InspireMD has voluntarily recalled its CGuard Prime 135 cm carotid stent delivery system in the US after performance issues were identified during a controlled launch. The recall does not affect the CGuard stent implant itself, which continues to show strong clinical results. The company plans to improve the delivery system design and expects FDA approval for the original CGuard delivery system in Q3 2026, with further approvals for related products anticipated in 2026 and 2027. InspireMD has withdrawn its 2026 revenue guidance due to the temporary sales pause but continues to see strong global demand for its stent technology.
Crédit Agricole S.A. disclosed its voting rights status as of June 30, 2026, reporting a total of 3,025,902,350 shares and an almost equal number of theoretical voting rights. The exercisable voting rights, accounting for shares held in treasury and ...
The Sweden flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031, at a 4.1% CAGR. Growth is driven by high influenza burden among seniors, increased demand for rapid molecular diagnostics...
In Q2 2026, NIU Technologies sold 434,687 electric mobility units, marking a 25% year-over-year increase in China with 402,202 units sold. Growth was fueled by strong demand for core and new smart electric models, including the NX 2026 long-range mot...
HSBC Continental Europe announced that no stabilisation activities were performed in relation to the EUR 750 million bond offering by Assicurazioni Generali S.p.A., which carries a 4.406% coupon due June 2037. This means the stabilisation manager did...
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to acquire David Brown Defence, a UK company specializing in high-precision gearboxes for naval and land defense. This acquisition will strengthen RENK's naval sector por...
